POlycythemia, Proteins and ErYthropoiesis

Launched by CENTRE HOSPITALIER UNIVERSITAIRE DIJON · Mar 25, 2025

Keywords

ClinConnect Summary

This clinical trial, named "POlycythemia, Proteins and ErYthropoiesis," is studying how certain proteins in the body affect the production of red blood cells, especially in patients with a condition called polycythemia, where there are too many red blood cells. The researchers want to understand how proteins like erythropoietin (a hormone that helps produce red blood cells) and other proteins related to iron metabolism play a role in this process. By measuring these proteins in the blood of patients with polycythemia and comparing them to those without the condition, the study aims to shed light on how red blood cell production is regulated.

To participate in this trial, individuals must be adults aged 65 to 74 who have been diagnosed with polycythemia, which is indicated by higher than normal hemoglobin levels (above 16 g/dl for women and above 16.5 g/dl for men) and have a known cause for their condition. There are also opportunities for individuals who have similar health issues but do not have polycythemia. Participants can expect to provide blood samples, which will help researchers gather important information about the proteins involved in red blood cell production. It's important to note that pregnant or nursing women, minors, and those unable to give consent are not eligible for this study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • - Persons who have given their non-opposition
• Patients with polycythemia:
• • haemoglobin value \> 16 g/dl female or \> 16.5 g/dl male
• • with a well-identified cause: either primary (polycythemia Vaquez, erythropoietin receptor or LNK/SH2B3 mutation...) or secondary \[cardio-respiratory pathologies, renal pathologies (post-transplant, polycystic kidney disease), metabolic pathologies, tumour (leiomyoma, pheochromocytoma...), constitutional mutations (hyperaffine haemoglobins, HIF2/EPAS1, PHD/EGLN1, VHL, ...)
• Patients control:
• • - persons with a similar pathology to that of polycythemia patients, essentialy secondary, but without polycythemia, i.e. with a haemoglobin value of \< 16 g/DL for women and \< 16.5 g/DL for men
• Exclusion Criteria:
• • Person subject to a measure of legal protection (guardianship, tutorship)
• • Person subject to a court order
• • Pregnant, parturient or nursing woman
• • Incapable of expressing consent
• • Minor